Drugs / Seralutinib
Seralutinib
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06423261 | Aug 2023 → Dec 2025 overdue | — | Zhejiang Echon Biopharm Limited | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03926793 | Feb 2020 → May 2021 | pulmonary arterial hypertension | Gossamer Bio, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03473236 | Sep 2017 → Dec 2018 | — | Gossamer Bio, Inc. | Completed | No outcome recorded |
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT04816604 | Apr 2021 → Dec 2027 expected | pulmonary arterial hypertension | Gossamer Bio, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04456998 | Nov 2020 → Oct 2022 | pulmonary arterial hypertension | Gossamer Bio, Inc. | Completed | Met primary |
| Phase 33 trials | ||||||
| Phase 3 | NCT07181382 | Feb 2026 → Dec 2028 | pulmonary hypertension owing to lung disease and/or hypoxia | GB002, Inc. | Suspended | No outcome recorded Stop: Business |
| Phase 3 | NCT06274801 | Sep 2024 → Dec 2026 expected | pulmonary arterial hypertension | GB002, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05934526 | Dec 2023 → Nov 2025 | pulmonary arterial hypertension | GB002, Inc. | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-05-06 | Chiesi Farmaceutici S.p.A. | Chiesi and Gossamer Bio Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in Pulmonary Arterial Hypertension and Other Respiratory Indications chiesi.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | seralutinib | “GB002 (seralutinib)” NCT04456998 ↗ |
| Known as | GB002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03473236 ↗ |
| Known as | PK-10571 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650333 ↗ |
| Action | Inhibit | “tyrosine kinase inhibitor targeting platelet-derived growth factor receptor (PDGFR) α/β, colony stimulating factor 1 receptor (CSF1R), and mast/stem cell growth factor receptor...” PMID 40788460 ↗ Aug 20252“Macrophage colony stimulating factor receptor inhibitor” CHEMBL4650333 ↗ “Stem cell growth factor receptor inhibitor” CHEMBL4650333 ↗ |
| Modality | Peptide | “GB002 recombinant peptide” NCT06423261 ↗ |
| Route | Inhaled | “Inhaled GB002” NCT03473236 ↗ |
| Target | CSF1R | “Macrophage colony stimulating factor receptor inhibitor” CHEMBL4650333 ↗ |
| Target | KIT | “Stem cell growth factor receptor inhibitor” CHEMBL4650333 ↗ |